Teflaro, Zinforo(ceftaroline fosamil)
Teflaro, Zinforo (ceftaroline fosamil) is a small molecule pharmaceutical. Ceftaroline fosamil was first approved as Teflaro on 2010-10-29. It is used to treat escherichia coli infections, infectious skin diseases, klebsiella infections, pneumonia, and staphylococcal infections amongst others in the USA. It has been approved in Europe to treat community-acquired infections, infectious skin diseases, and pneumonia.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Teflaro (generic drugs available since 2021-09-21)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftaroline fosamil
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TEFLARO | AbbVie | N-200327 RX | 2010-10-29 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| teflaro | New Drug Application | 2020-11-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| infectious skin diseases | — | D012874 | — |
| klebsiella infections | EFO_1001353 | D007710 | — |
| pneumonia | EFO_0003106 | D011014 | J18 |
| staphylococcal infections | — | D013203 | A49.01 |
| streptococcal infections | EFO_1001476 | D013290 | — |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J0712 | Injection, ceftaroline fosamil, 10 mg |
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | 1 | 2 | 2 | 5 | — | 8 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 1 | 2 | 2 | 1 | 6 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 3 | 1 | — | 4 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | — | 3 | — | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | 1 | — | 1 | — | 2 |
| Endocarditis | D004696 | EFO_0000465 | I33 | — | — | — | 2 | — | 2 |
| Community-acquired infections | D017714 | — | — | 1 | 1 | — | 2 | ||
| Critical illness | D016638 | — | — | — | 1 | — | 1 | ||
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
| Open fractures | D005597 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | A41.9 | — | 1 | — | — | — | 1 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Meningitis | D008581 | EFO_0000584 | G03 | 1 | — | — | — | — | 1 |
| Cerebrospinal fluid shunts | D002557 | 1 | — | — | — | — | 1 | ||
| Ventriculoperitoneal shunt | D017287 | 1 | — | — | — | — | 1 | ||
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | 1 | — | — | — | — | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEFTAROLINE FOSAMIL |
| INN | ceftaroline fosamil |
| Description | Ceftaroline fosamil is a cephalosporin having [4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl and {(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino side groups located at positions 3 and 7 respectively. The N-phospho prodrug of ceftaroline, a broad-spectrum antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA). It is used for the treatment of adults with acute bacterial skin and skin structure infections. It has a role as an antibacterial drug, an antimicrobial agent and a prodrug. It is an iminium betaine, a cephalosporin, a member of 1,3-thiazoles, an oxime O-ether, a member of thiadiazoles and an organic phosphoramidate. It is functionally related to a ceftaroline. |
| Classification | Small molecule |
| Drug class | cephalosporins; phosphoro-derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 229016-73-3 |
| RxCUI | 1040004 |
| ChEMBL ID | CHEMBL501122 |
| ChEBI ID | 70718 |
| PubChem CID | 9852981 |
| DrugBank | DB06590 |
| UNII ID | 7P6FQA5D21 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Teflaro - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Teflaro - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 699 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
47 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more